In-hospital initiation of PCSK9 inhibitors in ACS: pros and cons.
作者信息
Krychtiuk Konstantin A, Claeys Marc J, Gencer Baris, Mach François
机构信息
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Duke Clinical Research Institute, Durham, NC, USA.
出版信息
EuroIntervention. 2023 Jul 17;19(4):e283-e285. doi: 10.4244/EIJ-E-23-00014.
Abstract
摘要
相似文献
1
In-hospital initiation of PCSK9 inhibitors in ACS: pros and cons.急性冠状动脉综合征（ACS）患者住院期间启动前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂治疗：利弊分析
EuroIntervention. 2023 Jul 17;19(4):e283-e285. doi: 10.4244/EIJ-E-23-00014.
2
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?在 ACS 患者中的 PCSK9 抑制剂的院内应用：证据表明了什么？
Curr Atheroscler Rep. 2023 Jul;25(7):381-389. doi: 10.1007/s11883-023-01112-3. Epub 2023 May 24.
3
Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome.前蛋白转化酶枯草溶菌素9抑制剂（PCSK9i）在动脉粥样硬化性心血管疾病中的应用：欢迎真实世界数据
J Cardiovasc Pharmacol. 2023 May 1;81(5):336-338. doi: 10.1097/FJC.0000000000001411.
4
Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂降低脂蛋白(a)水平并降低心血管疾病风险
Atherosclerosis. 2022 Nov;361:30-31. doi: 10.1016/j.atherosclerosis.2022.10.010. Epub 2022 Oct 21.
5
Role of PCSK9 inhibitors in the management of dyslipidaemia.PCSK9 抑制剂在血脂异常管理中的作用。
Indian Heart J. 2024 Mar;76 Suppl 1(Suppl 1):S44-S50. doi: 10.1016/j.ihj.2023.12.011. Epub 2024 Jan 7.
6
Assessing Long-Term Liver Safety of Statins and PCSK9 Inhibitors Using Human Genetics.利用人类遗传学评估他汀类药物和PCSK9抑制剂的长期肝脏安全性。
Cell Mol Gastroenterol Hepatol. 2024;17(1):173-174. doi: 10.1016/j.jcmgh.2023.10.008. Epub 2023 Nov 6.
7
The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: A systematic review and meta-analysis.急性冠状动脉综合征患者早期院内使用前蛋白转化酶枯草溶菌素9抑制剂对心血管结局的影响：一项系统评价和荟萃分析。
Int J Cardiol. 2024 Mar 15;399:131775. doi: 10.1016/j.ijcard.2024.131775. Epub 2024 Jan 9.
8
Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.推荐在 LDL-C 升高的患者中使用依折麦布和/或 PCSK9 抑制剂。
Ann Intern Med. 2022 Aug;175(8):JC86. doi: 10.7326/J22-0060. Epub 2022 Aug 2.
9
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients.脂蛋白(a)与 PCSK9 抑制剂在紧急复杂高危和适应证患者中的获益。
Curr Med Sci. 2023 Dec;43(6):1206-1212. doi: 10.1007/s11596-023-2791-9. Epub 2023 Sep 27.
10
First-in-human gene editing for lipid lowering: the initial results.首次人体基因编辑降血脂：初步结果
Cardiovasc Res. 2024 Mar 30;120(4):e5-e8. doi: 10.1093/cvr/cvae037.
引用本文的文献
1
Lipid-Lowering Therapy after Acute Coronary Syndrome.急性冠状动脉综合征后的降脂治疗
J Clin Med. 2024 Apr 1;13(7):2043. doi: 10.3390/jcm13072043.
2
Lipid Lowering Drugs in Acute Coronary Syndromes (ACS).急性冠状动脉综合征（ACS）中的降脂药物。
Curr Atheroscler Rep. 2023 Dec;25(12):939-946. doi: 10.1007/s11883-023-01163-6. Epub 2023 Nov 28.
本文引用的文献
1
Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.急性冠脉综合征后 LDL-C 降低：早治疗，强治疗：从证据到临床实践。急性心血管护理协会（ACVC）联合欧洲预防心脏病学协会（EAPC）和欧洲心脏病学会心血管药物治疗工作组共同制定的临床共识声明。
Eur Heart J Acute Cardiovasc Care. 2022 Dec 27;11(12):939-949. doi: 10.1093/ehjacc/zuac123.
2
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.依洛尤单抗对心肌梗死后他汀类药物治疗患者的冠状动脉斑块表型和负担的影响。
JACC Cardiovasc Imaging. 2022 Jul;15(7):1308-1321. doi: 10.1016/j.jcmg.2022.03.002. Epub 2022 Mar 16.
3
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.依洛尤单抗联合高强度他汀治疗对急性心肌梗死患者冠状动脉粥样硬化的影响：PACMAN-AMI 随机临床试验。
JAMA. 2022 May 10;327(18):1771-1781. doi: 10.1001/jama.2022.5218.
4
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.基于 2019 ESC/EAS 和 2018 ACC/AHA 指南的 PCSK9 抑制剂的适应证。
Eur J Prev Cardiol. 2021 Mar 23;28(1):59-65. doi: 10.1177/2047487320940102. Epub 2020 Jul 20.
5
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.2020年欧洲心脏病学会非持续性ST段抬高型急性冠状动脉综合征患者管理指南
Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi: 10.1093/eurheartj/ehaa575.
6
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.依洛尤单抗对近期心肌梗死患者心血管结局的疗效： FOURIER 试验的预先设定的次要分析。
JAMA Cardiol. 2020 Aug 1;5(8):952-957. doi: 10.1001/jamacardio.2020.0882.
7
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
8
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).依洛尤单抗在急性冠状动脉综合征患者中早期降低 LDL 胆固醇水平的研究（EVOPACS）。
J Am Coll Cardiol. 2019 Nov 19;74(20):2452-2462. doi: 10.1016/j.jacc.2019.08.010. Epub 2019 Aug 31.
9
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.依洛尤单抗与急性冠脉综合征后的心血管结局。
N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.
10
Lipid management in ACS: Should we go lower faster?急性冠脉综合征中的血脂管理：我们是否应该更快地降低血脂？
Atherosclerosis. 2018 Aug;275:368-375. doi: 10.1016/j.atherosclerosis.2018.06.871. Epub 2018 Jun 22.
Zotero 插件